April 16, 2014
Astellas Pharma US Inc. has agreed to pay $7.3 million to settle a whistleblower False Claims Act suit from a former sales representative alleging that it marketed antifungal treatment Mycamine off-label for pediatric use and that as a result, Medicaid paid for unlawful prescriptions of the drug, the U.S. Department of Justice announced Wednesday.